Phase II Study of Liposomal Irinotecan for Advanced Refractory Gastric Cancer

Gastric Cancer Clinical Trial

Official title:

A Single-Center, Prospective Phase II Clinical Study of Liposomal Irinotecan Monotherapy for Third-Line and Beyond Recurrent/Refractory Advanced Gastric Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06437678
• Other study ID #: IRB-2024-498
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: May 27, 2024
• Est. completion date: February 28, 2026

Study information

• Verified date: May 2024
• Source: Zhejiang Cancer Hospital
• Contact: Xiangdong Cheng
• Phone: 13968032995
• Email: chengxd[@]zjcc.org.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the objective response rate (ORR) and disease control rate (DCR) of liposomal irinotecan monotherapy in the treatment of recurrent/refractory advanced gastric cancer.

Description:

This study is a single-arm, single-center, prospective clinical trial aimed at evaluating the efficacy and safety of liposomal irinotecan monotherapy in the treatment of recurrent/refractory advanced gastric cancer. The study targets patients with locally advanced, recurrent, or metastatic/previous treatment-refractory adenocarcinoma of the stomach or gastroesophageal junction. The primary endpoints of the study are objective response rate (ORR) and disease control rate (DCR). It plans to enroll 50 patients with locally advanced, recurrent, or metastatic/previous treatment-refractory adenocarcinoma of the stomach or gastroesophageal junction. Subjects will sign informed consent and undergo screening for eligibility before enrollment. Subjects will receive the following treatment: Liposomal Irinotecan Hydrochloride Injection (Ⅱ) 56.5mg/m2 every 2 weeks. Safety visits will be conducted on Day 1 of each treatment cycle, at the end of the study treatment, and 30 days (±7 days) after the end of the study treatment. Imaging assessments will be performed according to RECIST 1.1 criteria, including chest CT, enhanced CT scans of the abdomen and pelvis, or chest CT plain scan plus abdominal/pelvic MRI scan for patients allergic to contrast agents. Suspected cases of brain metastases will require brain enhanced MRI or enhanced CT. Bone scan examination will be conducted if bone metastases are suspected clinically or radiologically. Patients who discontinue treatment due to reasons other than radiological progression during the treatment period will undergo imaging examination at the end of treatment unless it has been conducted within 28 days. Subjects will undergo survival follow-up every 3 months after the end of treatment to collect and record survival status and subsequent anti-tumor treatment until death or loss to follow-up.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 50
• Est. completion date: February 28, 2026
• Est. primary completion date: February 28, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patients voluntarily join this study and sign an informed consent form;
• Age =18 years and =75 years;
• Pathologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma;
• CT or biopsy-confirmed recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma;
• Previously received at least one line of standard first- and second-line therapy (e.g., chemotherapy, targeted therapy), and experienced disease progression or intolerance;
• Interval of =4 weeks since previous chemotherapy, immunotherapy, or radiotherapy;
• Expected survival of =12 weeks;
• ECOG performance status score of 0-2;
• Normal major organ function, meeting the following criteria:

1. Hematologic criteria:

(No blood transfusion or blood products, and no use of G-CSF or other hematopoietic growth factors within 14 days) Absolute neutrophil count =1.5×10^9/L; Platelets =80×10^9/L; Hemoglobin =80 g/L.

2. Biochemical criteria:

Total bilirubin <1.5×ULN; ALT and AST =2.5×ULN (without liver metastasis) / ALT and AST =5×ULN (with liver metastasis); Serum creatinine =1.5×ULN or creatinine clearance >50 ml/min (Male: creatinine clearance = ((140 - age) × weight) / (72 × serum creatinine); Female: creatinine clearance = ((140 - age) × weight) / (72 × serum creatinine) × 0.85; weight in kg; serum creatinine in mg/mL).

3. Urine protein (semi-quantitative method) less than 2+;

4. Normal coagulation function (including INR, APTT, PT, FIB).

• Female participants of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose and agree to use effective contraception during the study and for 120 days after the last dose. Male participants with partners of childbearing potential must be surgically sterilized or agree to use effective contraception during the study and for 120 days after the last dose.

Exclusion Criteria:

• Having a history of or currently suffering from other malignant tumors;
• Previous or current use of irinotecan drugs;
• Having any chronic or significant disease deemed intolerable to treatment (e.g., severe heart disease, uncontrolled hypertension, significant liver or kidney dysfunction, etc.);
• History of gastrointestinal perforation, abdominal abscess, or recent (within 3 months) bowel obstruction, or imaging or clinical symptoms indicating the presence of bowel obstruction;
• Significant clinically relevant bleeding symptoms or a clear tendency to bleed within 3 months before the first dose of the study drug, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, or vasculitis; if fecal occult blood is positive at baseline, retesting is allowed. If retesting remains positive, a gastroscopy is required (unless gastroscopy has been performed within the past 3 months to exclude these conditions);
• Currently undergoing treatment for an active infection (e.g., requiring antibacterial, antiviral, or antifungal therapy);
• Active hepatitis (Hepatitis B: HBsAg positive and HBV DNA =500 IU/ml; Hepatitis C: HCV antibody positive and HCV RNA > upper limit of normal);
• Congenital or acquired immunodeficiency (e.g., HIV infection);
• Suffering from a mental illness that could interfere with consent or follow-up;
• Having any active autoimmune disease or a history of autoimmune disease with a risk of recurrence;
• Planned or previous organ or allogeneic bone marrow transplantation;
• Currently having interstitial pneumonia or interstitial lung disease, a history of interstitial pneumonia or interstitial lung disease requiring steroid treatment, or a screening CT showing active pneumonia or severe lung dysfunction; active tuberculosis;
• Currently using or recently used immunosuppressive drugs or systemic corticosteroids for immunosuppressive purposes;
• Received an attenuated live vaccine within 28 days before the first dose of the study drug, or requires such a vaccine during the treatment period or within 60 days after the last dose;
• Known allergy to any study drug or excipients;
• Breastfeeding women.

Related Conditions & MeSH terms

• Gastric Cancer
• Stomach Neoplasms

Intervention

Drug:
• Liposomal Irinotecan Hydrochloride
Liposomal Irinotecan Hydrochloride Injection (?) 56.5mg/m2 every 2 weeks

Locations

Country	Name	City	State
China	Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)	Hangzhou	Zhejiang

Sponsors (1)

Lead Sponsor	Collaborator
Zhejiang Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective response rate (ORR)	After treatment, the proportion of cancer patients whose tumors have shrunk to a predetermined value and can maintain the minimum time limit requirement is the sum of the complete response (CR) and partial response (PR) ratios.	through study completion, an average of 1 year
Primary	Disease Control Rate (DCR)	The percentage of evaluable cases in cancer patients who have improved their condition (CR+PR) and stabilized their condition (SD) after treatment.	through study completion, an average of 1 year
Secondary	OS (Overall survival)	The time between the date of enrollment and death caused by any reason.	Assessed up to 60 months